Komori
Waqoo (4937) · TargetAdvancedLatest Financial results briefing materials (2026-06-22): "Reframed"

Expanding from cosmetics into pharmaceuticals, regenerative medicine and aesthetic medicine

First written in FY2022-Q3. 5 of 8 entries say "Advanced", first in FY2022. Latest entry: 2026-06-22.

8entries
5years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022 – FY2024-Q22022: 220222023: 120232024: 220242025: 020252026: 32026
Same theme, other companies
Diversification by a cosmetics company into pharmaceuticals, regenerative medicine and aesthetic medicineA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2024-Q2AdvancedAnnual report

    「We have also begun planning and developing high-value-added products in the cosmetics field by fully utilizing Cellpro Japan’s technology and expertise.」

    The company progressed to planning and developing value-added products using Cellpro Japan’s technology and expertise.
  3. FY2024-Q1AdvancedAnnual report

    「Cellpro Japan and the company aim to strengthen integrated manufacturing and sales for outsourced blood-derived processing services in regenerative medicine. In cosmetics and product planning, we also believe we can develop highly effective products by closely collaborating with Cellpro Japan’s cosmetics and raw-material business and fully utilizing its technology and expertise.」

    The expansion strategy developed into integrating manufacturing and sales of blood-derived processing through the share exchange with Cellpro Japan and using its cosmetics and raw-material technology for product development.
  4. FY2023-Q2AdvancedAnnual report

    「Through our business alliance with SBC Medical Group, we are advancing our business around three growth strategies: I. Joint development of new products and wholesale sales of our existing products; II. Outsourced operation of advertising for clinics; and III. Establishment and expansion of a regenerative-medicine division.」

    The expansion strategy developed into joint product development and wholesale sales, outsourced clinic advertising and the establishment and expansion of a regenerative-medicine division.
  5. FY2022AdvancedAnnual report

    「We will pursue three growth strategies as a foundation for building a new business model for the future.」

    The plan to expand into pharmaceuticals, regenerative medicine and aesthetic medicine developed into three growth strategies.
  6. FY2022-Q3First statedAnnual report

    「Going forward, in addition to diversifying our cosmetics business, we plan to expand into product planning and development for pharmaceuticals and other products, with a focus on regenerative medicine and aesthetic medicine.」

    The company first disclosed plans to expand from cosmetics into pharmaceuticals, regenerative medicine and aesthetic medicine.
Moved together

"Launching the Medical Support business using D2C expertise and data" moved the same way as this thread, in the same document, in 4 of its 8 moves.

43222★12345
  1. ★This thread
  2. 1Launching the Medical Support business using D2C expertise and data4×
  3. 2Increase in shares and capital through exercise of stock acquisition rights3×
  4. 3Integrating manufacturing and sales in regenerative medicine2×
  5. 4Expanding the Aesthetic Medicine Business Through the Business Alliance with SBC Medical Group2×
  6. 5Acquiring New Customers and Increasing Cross-Selling Through Continued New Product Launches2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Waqoo yet. It last moved in the Financial results briefing materials of 2026-06-22: "Reframed".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expanding from cosmetics into pharmaceuticals, regenerative medicine and aesthetic medicine | Waqoo Inc. (4937) | Komori